"Debating the Accuracy of DNA Testing for Predicting Opioid Addiction Risk"
A DNA test called AvertD, approved by the FDA, claims to predict genetic risk of opioid addiction, but skeptics argue that it relies on unsound science and could lead to inappropriate prescribing or stigmatization of patients. The test analyzes 15 genetic markers and uses an algorithm to generate a risk score, but critics question its validity and potential biases. While the FDA approved the test with conditions and added warnings about its limitations, concerns remain about its real-world implications and impact on patient care.
